Effects of bevacizumab in retina and choroid after intravitreal injection into monkey eyes

Bibliography

• Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328-35
   PubMed Web of Science ®Google Scholar
• Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol 2004;137:496-503
   PubMed Web of Science ®Google Scholar
• Semenza GL. A new weapon for attacking tumor blood vessels. N Engl J Med 2008;358:2066-7
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5
   PubMed Web of Science ®Google Scholar
• Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol 2009;54:372-400
   PubMed Web of Science ®Google Scholar
• Scappaticci FA, Skillings JR, Holden SN, Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-9
   PubMed Web of Science ®Google Scholar
• Vaughn C, Zhang L, Schiff D. Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep 2008;10:86-91
   PubMedGoogle Scholar
• Velcheti V, Viswanathan A, Govindan R. The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with bevacizumab: a single institutional survey. J Thorac Oncol 2006;1:501
   PubMed Web of Science ®Google Scholar
• Eremina V, Jefferson JA, Kowalewska J, VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-36
   PubMed Web of Science ®Google Scholar
• Heiduschka P, Fietz H, Hofmeister S, Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814-23
   PubMed Web of Science ®Google Scholar
• Peters S, Heiduschka P, Julien S, Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007;143:995-1002
   PubMed Web of Science ®Google Scholar
• Meyer T, Robles-Carrillo L, Robson T, Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 2009;7:171-81
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Ying GS, Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908
   PubMed Web of Science ®Google Scholar
• Carneiro AM, Barthelmes D, Falcao MS, Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica 2011;225:211-21
   PubMed Web of Science ®Google Scholar
• Lim LS, Cheung CM, Mitchell P, Emerging evidence concerning systemic safety of anti-VEGF agents–should ophthalmologists be concerned? Am J Ophthalmol 2011;152:329-31
   PubMed Web of Science ®Google Scholar
• Nguyen DC, Scinicariello F, Attanasio R. Characterization and allelic polymorphisms of rhesus macaque (Macaca mulatta) IgG Fc receptor genes. Immunogenetics 2011;63:351-62
   PubMed Web of Science ®Google Scholar
• Schraermeyer U, Julien S. Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye. Graefes Arch Clin Exp Ophthalmol 2012;250:1303-1
   PubMed Web of Science ®Google Scholar
• Hunter WM, Greenwood FC. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 1962;194:495-6
   PubMed Web of Science ®Google Scholar
• Carstairs KC. The identification of platelets and platelet antigens in histological sections. J Pathol Bacteriol 1965;90:225-31
   PubMedGoogle Scholar
• Blaauwgeers HG, Holtkamp GM, Rutten H, Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 1999;155:421-8
   PubMed Web of Science ®Google Scholar
• Kim H, Robinson SB, Csaky KG. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis 2009;15:2803-12
   PubMed Web of Science ®Google Scholar
• Rappaport EF, Cassel DL, Walterhouse DO, A soluble form of the human Fc receptor Fc gamma RIIA: cloning, transcript analysis and detection. Exp Hematol 1993;21:689-96
   PubMed Web of Science ®Google Scholar
• Astier A, de la Salle H, Moncuit J, Detection and quantification of secreted soluble Fc gamma RIIA in human sera by an enzyme-linked immunosorbent assay. J Immunol Methods 1993;166:1-10
   PubMed Web of Science ®Google Scholar
• Wines BD, Gavin A, Powell MS, Soluble FcgammaRIIa inhibits rheumatoid factor binding to immune complexes. Immunology 2003;109:246-54
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400
   PubMed Web of Science ®Google Scholar
• Jeong KW, Lee JY, Lee SA, Dynamics of a heparin-binding domain of VEGF(165) complexed with its inhibitor triamterene. Biochemistry 2011;50:4843-54
   PubMed Web of Science ®Google Scholar
• Zhao W, McCallum SA, Xiao Z, Binding affinities of vascular endothelial growth factor (VEGF) for heparin-derived oligosaccharides. Biosci Rep 2012;32:71-81
   PubMed Web of Science ®Google Scholar
• Roux KH, Tankersley DL. A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype-anti-idiotype dimers in pooled human IgG. J Immunol 1990;144:1387-95
   PubMed Web of Science ®Google Scholar
• Boyle MJ, Richards JS, Gilson PR, Interactions with heparin-like molecules during erythrocyte invasion by Plasmodium falciparum merozoites. Blood 2010;115:4559-68
   PubMed Web of Science ®Google Scholar
• Tebo AE, Kremsner PG, Luty AJ. Fcgamma receptor-mediated phagocytosis of Plasmodium falciparum-infected erythrocytes in vitro. Clin Exp Immunol 2002;130:300-6
   PubMed Web of Science ®Google Scholar
• Vogt AM, Barragan A, Chen Q, Heparan sulfate on endothelial cells mediates the binding of Plasmodium falciparum-infected erythrocytes via the DBL1alpha domain of PfEMP1. Blood 2003;101:2405-11
   PubMed Web of Science ®Google Scholar
• Vogt AM, Winter G, Wahlgren M, Heparan sulphate identified on human erythrocytes: a Plasmodium falciparum receptor. Biochem J 2004;381:593-7
   PubMed Web of Science ®Google Scholar
• Bredius RG, Fijen CA, De Haas M, Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes. Immunology 1994;83:624-30
   Google Scholar
• Penha FM, Rodrigues EB, Furlani BA, Toxicological considerations for intravitreal drugs. Expert Opin Drug Metab Toxicol 2011;7:1021-34
   PubMed Web of Science ®Google Scholar
• von Hanno T, Kinge B, Fossen K. Retinal artery occlusion following intravitreal anti-VEGF therapy. Acta Ophthalmol 2010;88:263-6
   PubMed Web of Science ®Google Scholar
• Julien S, Schraermeyer U. Lipofuscin can be eliminated from the retinal pigment epithelium of monkeys. Neurobiol Aging 2012;33:2390-7
   PubMed Web of Science ®Google Scholar
• Fontaine O, Olivier S, Descovich D, The effect of intravitreal injection of bevacizumab on retinal circulation in patients with neovascular macular degeneration. Invest Ophthalmol Vis Sci 2011;52:7400-5
   PubMed Web of Science ®Google Scholar
• Barak A, Burgansky-Eliash Z, Barash H, The effect of intravitreal bevacizumab (Avastin) injection on retinal blood flow velocity in patients with choroidal neovascularization. Eur J Ophthalmol 2012;22:423-30
   PubMed Web of Science ®Google Scholar
• Hosseini H, Lotfi M, Esfahani MH, Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration. Retina 2012;32:967-71
   PubMed Web of Science ®Google Scholar
• Rasier R, Artunay O, Yuzbasioglu E, The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye (Lond) 2009;23:1714-18
   PubMed Web of Science ®Google Scholar
• Joseph R, Riddle JM, Welch KM, Platelet ultrastructure and secretion in acute ischemic stroke. Stroke 1989;20:1316-19
   PubMed Web of Science ®Google Scholar
• White JG. Electron opaque structures in human platelets: which are or are not dense bodies? Platelets 2008;19:455-66
   PubMed Web of Science ®Google Scholar
• Cleary CA, Sharaznayan D, Hickey-Dwyer M. Intravitreal anti-VEGF therapy for neovascular age-related macular degeneration and the risk of stroke. Ir Med J 2011;104:146-9
   PubMedGoogle Scholar
• Schmucker C, Ehlken C, Agostini HT, A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: off-Label versus Goldstandard. PLoS ONE 2012;7:e42701
   PubMed Web of Science ®Google Scholar
• Sakurai K, Akiyama H, Shimoda Y, Effect of intravitreal injection of high-dose bevacizumab in monkey eyes. Invest Ophthalmol Vis Sci 2009;50:4905-16
   PubMed Web of Science ®Google Scholar